Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3224-3232

  Sirijatuphat, Rujipas ^a   Limmahakhun, Samornrod ^a   Sirivatanauksorn, Vorapan ^a   Nation, Roger L ^b   Li, Jian ^b   Thamlikitkul, Visanu ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; COLISTIN; CREATININE; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ACETYLGLUCOSAMINIDASE; ACUTE PHASE PROTEIN; ANTIINFECTIVE AGENT; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY INJURY; LOADING DRUG DOSE; MALE; MORTALITY; NEPHROTOXICITY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK FACTOR; URINARY EXCRETION; ANIMAL; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; KIDNEY; METABOLISM; MIDDLE AGED;

ACETYLGLUCOSAMINIDASE; ACUTE-PHASE PROTEINS; ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; ASCORBIC ACID; COLISTIN; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY; LIPOCALIN-2; LIPOCALINS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS;

EID: 84930005825     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00280-15     Document Type: Article

References (59)

1. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. 2011. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 37:415-419. http://dx.doi.org/10.1016/j.ijantimicag.2011.01.012.
2. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, So TM, Yasin RM, Hsueh PR, Carlos CC, Hsu LY, Buntaran L, Lalitha MK, Kim MJ, Choi JY, Kim SI, Ko KS, Kang CI, Peck KR. 2011. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 184:1409-1417. http://dx.doi.org/10.1164/rccm.201102-0349OC.
3. Werarak P, Waiwarawut J, Tharavichitkul P, Pothirat C, Rungruanghiranya S, Geater SL, Chongthaleong A, Sittipunt C, Horsin P, Chalermskulrat W, Wiwatworapan T, Thummakul T, Mootsikapun P, Rungsrithong N, Supawita S, Chuchotthavorn C, Tongsai S, Thamlikitkul V. 2012. Acinetobacter baumannii nosocomial pneumonia in tertiary care hospitals in Thailand. J Med Assoc Thai 95(Suppl 2):S23-S33.
4. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. 2012. 'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 25:626-633. http://dx.doi.org/10.1097/QCO.0b013e328358afe5.
5. Barnett M, Bushby SR, Wilkinson S. 1964. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 23:552-574. http://dx.doi.org/10.1111/j.1476-5381.1964.tb01610.x.
6. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953-1958. http://dx.doi.org/10.1128/AAC.00035-06.
7. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. 2012. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 10:917-934. http://dx.doi.org/10.1586/eri.12.78.
8. Falagas ME, Rafailidis PI. 2009. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 48:1729-1731. http://dx.doi.org/10.1086/599226.
9. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53:879-884. http://dx.doi.org/10.1093/cid/cir611.
10. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48:1724-1728. http://dx.doi.org/10.1086/599225.
11. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M. 2007. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 33:1162-1167. http://dx.doi.org/10.1007/s00134-007-0675-2.
12. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. 2007. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 11:402-406. http://dx.doi.org/10.1016/j.ijid.2006.09.011.
13. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. 2005. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11:115-121. http://dx.doi.org/10.1111/j.1469-0691.2004.01043.x.
14. Sorli L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. 2013. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13:380. http://dx.doi.org/10.1186/1471-2334-13-380.
15. Forrest A, Silveira FP, Thamlikitkul V, Garonzik SM, Mandragos K, Shoham S, Paterson DL, Li J, Nation RL. 2014. Toxicodynamics for colistin-associated changes in creatinine clearance. Abstr Intersci Conf Antimicrob Agents Chemother. http://www.icaac.org/.
16. Deryke CA, Crawford AJ, Uddin N, Wallace MR. 2010. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54:4503-4505. http://dx.doi.org/10.1128/AAC.01707-09.
17. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56:4625-4629. http://dx.doi.org/10.1128/AAC.00280-12.
18. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 47:1766-1770. http://dx.doi.org/10.1128/AAC.47.5.1766-1770.2003.
19. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
20. Ma Z, Wang J, Nation RL, Li J, Turnidge JD, Coulthard K, Milne RW. 2009. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother 53:2857-2864. http://dx.doi.org/10.1128/AAC.00030-09.
21. Azad MA, Roberts KD, Yu HH, Liu B, Schofield AV, James SA, Howard DL, Nation RL, Rogers K, de Jonge MD, Thompson PE, Fu J, Velkov T, Li J. 2015. Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach. Anal Chem 87:1590-1595. http://dx.doi.org/10.1021/ac504516k.
22. Yousef JM, Chen G, Hill PA, Nation RL, Li J. 2011. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55:4044-4049. http://dx.doi.org/10.1128/AAC.00328-11.
23. Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH. 2014. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 58:4200-4202. http://dx.doi.org/10.1128/AAC.02557-14.
24. De S, Kuwahara S, Saito A. 2014. The endocytic receptor megalin and its associated proteins in proximal tubule epithelial cells. Membranes (Basel) 4:333-355. http://dx.doi.org/10.3390/membranes4030333.
25. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI. 1995. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 96:1404-1413. http://dx.doi.org/10.1172/JCI118176.
26. Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. 2013. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 57:6319-6324. http://dx.doi.org/10.1128/AAC.00254-13.
27. Ozyilmaz E, Ebinc FA, Derici U, Gulbahar O, Goktas G, Elmas C, Oguzulgen IK, Sindel S. 2011. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 37:141-146. http://dx.doi.org/10.1007/s00134-010-2038-7.
28. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. 2011. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79:33-45. http://dx.doi.org/10.1038/ki.2010.337.
29. Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC. 2007. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 81:495-504. http://dx.doi.org/10.1007/s00204-006-0173-2.
30. Oktem F, Arslan MK, Ozguner F, Candir O, Yilmaz HR, Ciris M, Uz E. 2005. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 215:227-233. http://dx.doi.org/10.1016/j.tox.2005.07.009.
31. Niki E. 1991. Action of ascorbic acid as a scavenger of active and stable oxygen radicals. Am J Clin Nutr 54:1119S-1124S.
32. Padh H. 1990. Cellular functions of ascorbic acid. Biochem Cell Biol 68:1166-1173. http://dx.doi.org/10.1139/o90-173.
33. Tolbert BM. 1985. Metabolism and function of ascorbic acid and its metabolites. Int J Vitam Nutr Res Suppl 27:121-138.
34. Lloberas N, Torras J, Herrero-Fresneda I, Cruzado JM, Riera M, Hurtado I, Grinyo JM. 2002. Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J 16:908-910. http://dx.doi.org/10.1096/fj.01-0880fje.
35. Durak I, Ozbek H, Karaayvaz M, Ozturk HS. 2002. Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity. Drug Chem Toxicol 25:1-8. http://dx.doi.org/10.1081/DCT-100108468.
36. Kadkhodaee M, Khastar H, Arab HA, Ghaznavi R, Zahmatkesh M, Mahdavi-Mazdeh M. 2007. Antioxidant vitamins preserve superoxide dismutase activities in gentamicin-induced nephrotoxicity. Transplant Proc 39:864-865. http://dx.doi.org/10.1016/j.transproceed.2007.02.038.
37. Ocak S, Gorur S, Hakverdi S, Celik S, Erdogan S. 2007. Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats. Basic Clin Pharmacol Toxicol 100:328-333. http://dx.doi.org/10.1111/j.1742-7843.2007.00051.x.
38. Yousef JM, Chen G, Hill PA, Nation RL, Li J. 2012. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67:452-459. http://dx.doi.org/10.1093/jac/dkr483.
39. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
40. Anonymous. 2002. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1-S266. http://dx.doi.org/10.1016/S0272-6386(02)70081-4.
41. Winter MA, Guhr KN, Berg GM. 2012. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy 32:604-612. http://dx.doi.org/10.1002/j.1875-9114.2012.01098.x.
42. Dudhani RV, Nation RL, Li J. 2010. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 65:1412-1415. http://dx.doi.org/10.1093/jac/dkq134.
43. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. http://dx.doi.org/10.1128/AAC.01733-10.
44. Moon JM, Chun BJ. 2011. The efficacy of high doses of vitamin C in patients with paraquat poisoning. Hum Exp Toxicol 30:844-850. http://dx.doi.org/10.1177/0960327110385633.
45. Auer BL, Auer D, Rodgers AL. 1998. The effect of ascorbic acid ingestion on the biochemical and physicochemical risk factors associated with calcium oxalate kidney stone formation. Clin Chem Lab Med 36:143-147.
46. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV. 2004. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110:2837-2842. http://dx.doi.org/10.1161/01.CIR.0000146396.19081.73.
47. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. 2011. Risk factors for colistin-associated nephrotoxicity. J Infect 62:187-190. http://dx.doi.org/10.1016/j.jinf.2010.11.013.
48. Han WK, Wagener G, Zhu Y, Wang S, Lee HT. 2009. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 4:873-882. http://dx.doi.org/10.2215/CJN.04810908.
49. Kunin CM, Chesney RW, Craig WA, England AC, DeAngelis C. 1978. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase in the general population and in patients with renal disease. Pediatrics 62:751-760.
50. Azad MA, Finnin BA, Poudyal A, Davis K, Li J, Hill PA, Nation RL, Velkov T. 24 June 2013. Polymyxin B induces apoptosis in kidney proximal tubular cells. Antimicrob Agents Chemother http://dx.doi.org/10.1128/AAC.02587-12.
51. Boldt J, Brenner T, Lehmann A, Lang J, Kumle B, Werling C. 2003. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med 29:763-769. http://dx.doi.org/10.1007/s00134-003-1702-6.
52. Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D, Morgan TJ. 2003. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 18:543-551. http://dx.doi.org/10.1093/ndt/18.3.543.
53. Chew SL, Lins RL, Daelemans R, Nuyts GD, De Broe ME. 1993. Urinary enzymes in acute renal failure. Nephrol Dial Transplant 8:507-511.
54. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. 2007. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18:407-413. http://dx.doi.org/10.1681/ASN.2006080882.
55. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. 2003. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534-2543. http://dx.doi.org/10.1097/01.ASN.0000088027.54400.C6.
56. Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, Ronco C. 2010. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 36:444-451. http://dx.doi.org/10.1007/s00134-009-1711-1.
57. Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, Haase M. 2009. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery - a prospective cohort study. Crit Care Med 37:553-560. http://dx.doi.org/10.1097/CCM.0b013e318195846e.
58. Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. FASEB J 22:659-661. http://dx.doi.org/10.1096/fj.07-9574LSF.
59. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. 2007. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334:197. http://dx.doi.org/10.1136/bmj.39048.407928.BE.